Suppr超能文献

肝素亲和层析预测抗体通过胞饮作用的清除率。

Heparin chromatography as an predictor for antibody clearance rate through pinocytosis.

机构信息

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

出版信息

MAbs. 2020 Jan-Dec;12(1):1683432. doi: 10.1080/19420862.2019.1683432.

Abstract

The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several efficacious and safe therapeutic options, convenience (determined by dosing interval or route of application), which is mainly driven by PK properties, can affect drug selection. Therapeutic antibodies can have greatly different PK even if they have identical Fc domains and show no target-mediated drug disposition. Biophysical properties like surface charge or hydrophobicity, and binding to surrogates for high abundant off-targets (e.g., baculovirus particles, Chinese hamster ovary cell membrane proteins) were proposed to be responsible for these differences. Here, we used heparin chromatography to separate a polyclonal mix of endogenous human IgGs (IVIG) into fractions that differ in their PK properties. Heparin was chosen as a surrogate for highly negatively charged glycocalyx components on endothelial cells, which are among the main contributors to nonspecific clearance. By directly correlating heparin retention time with clearance, we identified heparin chromatography as a tool to assess differences in unspecific cell-surface interaction and the likelihood for increased pinocytotic uptake and degradation. Building on these results, we combined predictors for FcRn-mediated recycling and cell-surface interaction. The combination of heparin and FcRn chromatography allow identification of antibodies with abnormal PK by mimicking the major root causes for fast, non-target-mediated, clearance of therapeutic, Fc-containing proteins.

摘要

治疗性抗体的药代动力学(PK)特性直接影响疗效、剂量和剂量间隔、应用途径和组织穿透性。在有多种有效和安全的治疗选择可供医疗保健提供者和患者选择的适应症中,便利性(由剂量间隔或应用途径决定),主要由 PK 特性决定,可能会影响药物选择。治疗性抗体即使具有相同的 Fc 结构域且不存在靶向介导的药物处置,也可能具有很大的 PK 差异。表面电荷或疏水性等生物物理特性,以及与高丰度非靶点的替代物(例如,杆状病毒颗粒、中国仓鼠卵巢细胞膜蛋白)结合,被认为是造成这些差异的原因。在这里,我们使用肝素层析将多克隆混合的内源性人 IgGs(IVIG)分离成在 PK 特性上不同的组分。肝素被选为内皮细胞上高度带负电荷的糖萼成分的替代物,这些成分是非特异性清除的主要贡献者之一。通过将肝素保留时间与清除率直接相关,我们确定肝素层析是一种评估非特异性细胞表面相互作用差异以及增加胞饮摄取和降解可能性的工具。基于这些结果,我们结合了预测 FcRn 介导的循环和细胞表面相互作用的预测因子。肝素和 FcRn 层析的结合可以通过模拟治疗性 Fc 蛋白快速、非靶向介导清除的主要根本原因来识别具有异常 PK 的抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bb1/6927760/668ea70c2e33/kmab-12-01-1683432-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验